Search results
Results from the WOW.Com Content Network
It is approved in the United States [8] and Canada, [9] and the European Union [5] to treat systemic lupus erythematosus and lupus nephritis. [10] The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea ...
Because systemic administration results in blockading the same pathway in both healthy and diseased tissue, pharmacology is exaggerated leading to many side effects such as lymphoma, infections, congestive heart failure, demyelinating disease, a lupus-like syndrome, injection site reactions, and additional systemic side effects. [10]
Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus aureus bi-component ...
The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final ...
Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. [2] [4] It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.
Drug-induced lupus erythematosus is an autoimmune disorder caused by chronic use of certain drugs. These drugs cause an autoimmune response (the body attacks its own cells) producing symptoms similar to those of systemic lupus erythematosus (SLE).
In blood samples of people with lupus, the researchers also tested the effects of adding a small molecule that activates the aryl hydrocarbon receptor. They found that it limited the accumulation ...
Severe reactions may result in cutaneous necrosis at the injection site, typically presenting in one of two forms: (1) those associated with intravenous infusion or (2) those related to intramuscular injection. [7]: 123–4 Intramuscular injections may produce a syndrome called livedo dermatitis. [7]: 124